Delaware
|
2834
|
04-3321804
|
||
(State
or other jurisdiction
of
incorporation or organization)
|
(Primary
Standard Industrial
Classification
Code Number)
|
(I.R.S.
Employer
Identification
Number)
|
Large
accelerated filer
¨
|
Accelerated
filer
¨
|
Non-accelerated
filer
¨
|
Smaller
reporting company
x
|
Title
of Each Class of
Securities
to be
Registered
|
Amount
being
registered
|
Proposed
Maximum
Offering
Price Per
Security
|
Proposed
Maximum
Aggregate
Offering
Price
|
Amount
of
Registration
Fee
|
||||||||||||
Common
Stock, par value $0.00001 per share
|
$ | $ | $ | |||||||||||||
Warrants
to purchase Common Stock
|
$ | $ | $ | |||||||||||||
Common
Stock issuable upon exercise of Warrants
|
$ | $ | $ | |||||||||||||
Total
|
60,000,000 | (1) | $ | 0.19 | $ | 11,400,000 | $ | 813 | * |
(1)
|
Pursuant
to Rule 416, the securities being registered hereunder include such
indeterminate number of additional shares of common stock as may be issued
after the date hereof as a result of stock splits, stock dividends or
similar transactions.
|
*
|
Previously paid. |
Per Unit
|
Total
|
|||||||
Public
offering price
|
$ | $ | ||||||
Placement
Agent’s Fees (1)
|
$ | $ | ||||||
Proceeds,
before expenses, to us
|
$ | $ |
(1)
|
We
will also reimburse the placement agent’s accountable expenses in an
amount equal to 1% of gross offering proceeds, subject to a cap of
$35,000.
|
Page
|
||
PROSPECTUS
SUMMARY
|
6
|
|
RISK
FACTORS
|
10
|
|
FORWARD-LOOKING
STATEMENTS
|
22
|
|
USE
OF PROCEEDS
|
24
|
|
MARKET
FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
|
25
|
|
DILUTION
|
25
|
|
MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
26
|
|
BUSINESS
|
32
|
|
LITIGATION
|
40
|
|
PROPERTIES
|
40
|
|
MANAGEMENT
|
41
|
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
48
|
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
|
52
|
|
PLAN
OF DISTRIBUTION
|
52
|
|
DESCRIPTION
OF SECURITIES
|
53
|
|
DISCLOSURE
OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT
LIABILITIES
|
58
|
|
WHERE
YOU CAN FIND MORE INFORMATION
|
58
|
|
LEGAL
MATTERS
|
58
|
|
EXPERTS
|
58
|
|
FINANCIAL
STATEMENTS
|
F-1
|
Securities
offered by us:
|
|
Up
to 34,285,714 units. Each unit will consist of one share of our
common stock and a warrant to purchase 0.75 shares of our common
stock.
|
Offering
Price:
|
|
$ per
unit.
|
Description
of Warrants:
|
|
The
warrants will be exercisable on or after the applicable closing date of
this offering through and including close of business on the fifth
anniversary of the date of issuance at an exercise price equal to 100% of
the unit price. The warrants will be exercisable exclusively on
a cashless basis unless, at the time of exercise, the issuance of the
shares underlying the warrants is covered by an effective registration
statement under the Securities Act of 1933, as
amended.
|
•
|
an
aggregate of 8,153,158 shares of common stock issuable upon the
exercise of outstanding stock options issued to employees, directors and
consultants, including under our 2000 Stock Option and Incentive Plan and
our 2006 Stock Incentive Plan;
|
|
•
|
an
aggregate of 3,290,000 additional shares of common stock reserved for
future issuance under our 2006 Stock Incentive Plan;
|
|
•
|
an
aggregate of 35,171,073 additional shares of common stock reserved for
issuance upon conversion of our outstanding shares of Series C and Series
E preferred stock, excluding conversion of accumulated but unpaid
dividends;
|
|
•
|
an
aggregate of 21,788,526 additional shares of common stock
reserved for issuance under various outstanding warrant agreements, with
expiration dates between August 9, 2010 and December 31, 2015,
at exercise prices ranging from $0.65 to $1.72; and
|
|
•
|
shares of common stock issuable upon exercise of
the warrants included in the offered units.
|
|
Unless
we specifically state otherwise, the share information in this prospectus
is as of July 6, 2010 and reflects or assumes no exercise of outstanding
options or warrants to purchase shares of our common
stock.
|
Summary
Financial Information
The
following table summarizes our financial data. We have
derived the following summary of our statements of operations data
for the three months ended March 31, 2010 and 2009 from our
unaudited financial statements appearing elsewhere in this
prospectus. We have derived the following summary of our statements
of operations data for the fiscal years ended December 31, 2009 and 2008
from our audited financial statements appearing elsewhere in this
prospectus. The following summary of our financial data
set forth below should be read together with our financial statements
and the related notes to those statements, as well as the section titled
“Management’s Discussion and Analysis of Financial Condition and Results
of Operations,” appearing elsewhere in this prospectus.
|
Statement of Operations Data:
|
Three Months Ended
March 31,
|
Year Ended
December 31,
|
||||||||||||
2010
|
2009
|
2009
|
2008
|
|||||||||||
Revenues
|
$
|
8,333
|
$
|
30,968
|
$
|
96,314
|
$
|
125,968
|
||||||
Costs
and expenses
|
2,555,652
|
2,260,029
|
10,262,495
|
16,716,985
|
||||||||||
Other
income (expense)
|
7,897,441
|
415,616
|
(12,107,125
|
)
|
139,611
|
|||||||||
Net
income (loss)
|
5,350,122
|
(1,813,445
|
)
|
(22,273,306
|
)
|
(16,451,406
|
)
|
|||||||
Net
income (loss) attributable to common stockholders
|
4,693,487
|
(3,295,659
|
)
|
(26,283,626
|
)
|
(22,960,823
|
)
|
|||||||
Balance
Sheet Data:
|
||||||||||||||
Current
assets
|
5,762,229
|
7,062,907
|
8,872,452
|
1,392,237
|
||||||||||
Current
liabilities
|
5,865,908
|
4,942,289
|
16,967,818
|
6,617,206
|
||||||||||
Total
assets
|
5,794,386
|
7,130,477
|
8,931,899
|
1,466,038
|
||||||||||
·
|
the
number of potential products and technologies in
development;
|
|
·
|
continued
progress and cost of our research and development
programs;
|
|
·
|
progress
with pre-clinical studies and clinical trials;
|
|
·
|
the
time and costs involved in obtaining regulatory
clearance;
|
|
·
|
costs
involved in preparing, filing, prosecuting, maintaining and enforcing
patent claims;
|
|
·
|
costs
of developing sales, marketing and distribution channels and our ability
to sell our drugs;
|
|
·
|
costs
involved in establishing manufacturing capabilities for clinical trial and
commercial quantities of our drugs;
|
|
·
|
competing
technological and market developments;
|
|
·
|
market
acceptance of our products;
|
|
·
|
costs
for recruiting and retaining management, employees and
consultants;
|
|
·
|
costs
for educating physicians;
|
|
·
|
our
status as a Bulletin Board-listed company and the prospects for our stock
being listed on a national exchange;
|
|
·
|
uncertainty
and economic instability resulting from terrorist acts and other acts of
violence or war; and
|
|
·
|
the
condition of capital markets and the economy generally, both in the U.S.
and globally.
|
·
|
demonstrating
benefit from delivery of each specific drug for specific medical
indications;
|
|
·
|
demonstrating
through pre-clinical and clinical trials that each drug is safe and
effective; and
|
|
·
|
demonstrating
that we have established viable Good Manufacturing Practices capable of
potential scale-up.
|
·
|
uncertainties
arising from the rapidly growing scientific aspects of drug therapies and
potential treatments;
|
|
·
|
uncertainties
arising as a result of the broad array of alternative potential treatments
related to cancer, hepatitis and other diseases; and
|
|
·
|
anticipated
expense and time believed to be associated with the development and
regulatory approval of treatments for cancer, hepatitis and other
diseases.
|
·
|
the
receipt of regulatory clearance of marketing claims for the uses that we
are developing;
|
|
·
|
the
establishment and demonstration of the advantages, safety and efficacy of
our technologies;
|
|
·
|
pricing
and reimbursement policies of government and third-party payers such as
insurance companies, health maintenance organizations and other health
plan administrators;
|
|
·
|
our
ability to attract corporate partners, including pharmaceutical companies,
to assist in commercializing our intended products; and
|
|
·
|
our
ability to market our products.
|
·
|
cease
selling, incorporating or using any of our technologies and/or products
that incorporate the challenged intellectual property, which would
adversely affect our ability to generate revenue;
|
|
·
|
obtain
a license from the holder of the infringed intellectual property right,
which license may be costly or may not be available on reasonable terms,
if at all; or
|
|
·
|
redesign
our products, which would be costly and
time-consuming.
|
·
|
fail
to adequately market our products;
|
|
·
|
fail
to satisfy financial or contractual obligations to us;
|
|
·
|
offer,
design, manufacture or promote competing products; or
|
|
·
|
cease
operations with little or no
notice.
|
·
|
announcements
or press releases relating to the biopharmaceutical sector or to our own
business or prospects;
|
|
·
|
regulatory,
legislative, or other developments affecting us or the healthcare industry
generally;
|
|
·
|
the
dilutive effect of conversion of our Series E or Series C preferred stock
into common stock or the exercise of options and
warrants;
|
|
·
|
sales
by those financing our company through convertible securities and warrants
of the underlying common stock, when it is registered with the SEC and may
be sold into the public market, immediately upon conversion or exercise;
and
|
|
·
|
market
conditions specific to biopharmaceutical companies, the healthcare
industry and the stock market
generally.
|
·
|
the
election of directors;
|
|
·
|
the
amendment of charter documents;
|
|
·
|
issuance
of blank-check preferred or convertible stock, notes or instruments of
indebtedness which may have conversion, liquidation and similar features,
or completion of other financing arrangements including certain issuances
of common stock; or
|
|
·
|
the
approval of certain mergers and other significant corporate transactions,
including a sale of substantially all of our assets (and in the case of
licensing, any material intellectual property), or merger with a
publicly-traded shell or other
company.
|
·
|
selling
or otherwise granting any rights with respect to all or substantially all
of our assets (and in the case of licensing, any material intellectual
property) or the Company's business and we shall not enter into a merger
or consolidation with another company unless we are the surviving
corporation, the Series E preferred stock remains outstanding, there are
no changes to the rights and preferences of the Series E preferred stock
and there is not created any new class of capital stock senior to the
Series E preferred stock;
|
|
·
|
redeeming
or repurchasing any capital stock other than Series E preferred stock or
the related warrants; or
|
|
·
|
incurring
any new debt for borrowed money in excess of
$500,000.
|
•
|
to
fund our research and development activities, including the further
development of NOV-002 in breast cancer and other solid tumors;
and
|
|
•
|
for
general corporate purposes, such as general and administrative expenses,
capital expenditures, working capital, prosecution and maintenance of our
intellectual property and the potential investment in technologies or
products that complement our
business.
|
Fiscal
Year 2008
|
High
|
Low
|
||||||
First
Quarter
|
$
|
0.82
|
$
|
0.43
|
||||
Second
Quarter
|
0.64
|
0.44
|
||||||
Third
Quarter
|
0.54
|
0.35
|
||||||
Fourth
Quarter
|
0.49
|
0.19
|
Fiscal
Year 2009
|
High
|
Low
|
||||||
First
Quarter
|
$
|
0.60
|
$
|
0.30
|
||||
Second
Quarter
|
0.90
|
0.34
|
||||||
Third
Quarter
|
0.98
|
0.57
|
||||||
Fourth
Quarter
|
2.90
|
0.65
|
Fiscal
Year 2010
|
High
|
Low
|
||||||
First
Quarter
|
$
|
3.05
|
$
|
0.17
|
||||
Second
Quarter
|
0.28
|
0.10
|
||||||
Third Quarter (through July 6, 2010) | 0.12 | 0.09 |
Public
offering price per unit
|
$ | |||
Net
tangible book value per share as of March 31, 2010
|
$ | |||
Increase
per share attributable to sale of securities to investors
|
$ | |||
As
adjusted net tangible book value per share after the
offering
|
$ | |||
Dilution
per share to investors
|
$ | |||
Dilution
as a percentage of the offering price
|
|
%
|
|
·
|
When added to cells, NOV-002
results in generation of a mild and transient oxidative signal at the cell
surface and intracellularly, glutathionylation of redox-sensitive proteins
and a range of biochemical/molecular effects that are dependent on cell
type and status, leading to alteration of cell
functions.
|
|
·
|
In tumor cells, redox modulation
by NOV-002 has been shown to decrease the rate of tumor cell
proliferation. For example, in a human ovarian tumor cell line (SKOV3),
NOV-002 induced an intracellular oxidative signal (as evidenced by
generation of reactive oxygen species), increased levels of active (i.e.
phosphorylated) c-Jun N-terminal kinases (a component of cell signaling
pathways regulating proliferation) and decreased the rate of tumor cell
proliferation. This was also accompanied by increased tumor cell
apoptosis.
|
|
·
|
Also in tumor cells, NOV-002
decreased signaling through a redox-regulated pathway known to control
cell migration, invasiveness and metastasis and inhibited invasiveness of
a variety of human tumor cell
types.
|
|
·
|
In animal tumor models, NOV-002
has been shown to increase anti-tumor immune responsiveness and to inhibit
tumor growth and enhance survival when combined with
chemotherapy.
|
|
In a mouse model of colon cancer,
NOV-002 significantly increased anti-tumor response and survival when
combined with chemotherapy
(cyclophosphamide).
|
|
o
|
In a mouse model of melanoma
where animals were treated with a form of immunotherapy (adoptive T cell
transfer) together with chemotherapy (cyclophosphamide) the addition of
NOV-002 significantly reduced the rate of tumor growth and increased
survival.
|
|
o
|
In a mouse ovarian cancer model,
animals treated with NOV-002 alone showed a significantly increased
tumor-specific cellular immune response (interferon gamma production)
compared to control mice treated with a saline
vehicle.
|
|
·
|
In contrast to these suppressive
effects on tumors, similar redox modulation, protein glutathionylation and
cell signaling pathway effects from NOV-002 treatment resulted in
increased proliferation in myeloid lineage cells such as HL-60 cells.
Furthermore,
in
vivo
, NOV-002
treatment of chemosuppressed mice (using cyclophosphamide) led to
increased total bone marrow cell number and proliferation of multi-lineage
bone marrow progenitor cells (i.e., progenitor cells for white cells, red
cells and platelets).
|
Name
|
Age
|
Position
|
||
Stephen
A. Hill, B.M. B.Ch., M.A., F.R.C.S.
|
51
|
Chairman
of the Board
|
||
Harry
S. Palmin
|
40
|
President,
Chief Executive Officer and Director
|
||
Elias
B. Nyberg, DVM, BVSc, MACVS, MRCVS, MBA
|
55
|
Vice
President of Regulatory, Quality and Compliance
|
||
Christopher
J. Pazoles, Ph.D.
|
60
|
Vice
President of Research and Development
|
||
Joanne
M. Protano
|
41
|
Vice
President, Chief Financial Officer and Treasurer
|
||
Kristin
C. Schuhwerk
|
39
|
Vice
President of Clinical Development and Operations
|
||
Michael
J. Doyle (1) (2) (3)
|
51
|
Director
|
||
Sim
Fass, Ph.D. (1) (2) (3)
|
68
|
Director
|
||
James
S. Manuso, Ph.D.
|
61
|
Director
|
||
David
B. McWilliams (2) (3)
|
66
|
Director
|
||
Howard
M. Schneider (1) (3)
|
66
|
Director
|
Name and Principal Position
|
Year
|
Salary
($)
|
Bonus
($) (3)
|
Option
Awards ($)
(4)
|
All other
compensation
($)
|
Total ($)
|
||||||||||||||||
Harry
S. Palmin (1)
|
2009
|
$ | 270,000 | $ | 40,500 | $ | 131,650 | $ | 0 | $ | 442,150 | |||||||||||
President,
Chief Executive Officer
|
2008
|
$ | 270,000 | $ | 40,500 | $ | 110,560 | $ | 0 | $ | 421,060 | |||||||||||
Christopher
J. Pazoles (1)
|
2009
|
$ | 235,000 | $ | 35,250 | $ | 105,320 | $ | 0 | $ | 375,570 | |||||||||||
Vice
President of Research and Development
|
2008
|
$ | 235,000 | $ | 35,250 | $ | 55,280 | $ | 0 | $ | 325,530 | |||||||||||
Elias
B. Nyberg (1) (2)
|
2009
|
$ | 225,000 | $ | 33,750 | $ | 78,990 | $ | 0 | $ | 337,740 | |||||||||||
Vice
President of Regulatory, Quality and Compliance
|
2008
|
$ | 168,750 | $ | 25,313 | $ | 93,160 | $ | 0 | $ | 287,223 |
(1)
|
There
has been no increase to executive base salaries for
2010.
|
(2)
|
Dr.
Nyberg’s employment with the Company commenced on April 1,
2008.
|
(3)
|
Bonus
amounts for 2009 were paid in 2010. Bonus amounts for 2008 were paid
in 2009.
|
(4)
|
The
fair value of each stock award was estimated on the grant date using the
Black-Scholes option-pricing model. See Note 7 to the financial statements
for a description of the assumptions used in estimating the fair value of
stock options.
|
Individual Grants
|
||||||||||||||||
Name
|
Year
of Grant
|
Number of
securities
underlying
unexercised
options
(#)
exercisable
|
Number of
securities
underlying
unexercised
options
(#)
unexercisable
|
Exercise or
base price
($/share)
|
Expiration
date
|
|||||||||||
Harry
S. Palmin
|
2009 | (1) | — | 250,000 | $ | 0.75 |
12/8/2019
|
|||||||||
2008 | (2) | 133,333 | 266,667 | 0.43 |
12/15/2018
|
|||||||||||
2007 | (2) | 133,333 | 66,667 | 0.45 |
12/17/2017
|
|||||||||||
2006 | (2) | 150,000 | — | 0.91 |
12/11/2016
|
|||||||||||
2005 | (3) | 250,000 | — | 0.01 |
1/31/2015
|
|||||||||||
2005 | (3) | 150,000 | — | 0.01 |
3/31/2015
|
|||||||||||
2004 | (4) | 330,000 | — | 0.01 |
4/1/2014
|
|||||||||||
2003 | (5) | 7,130 | — | 0.70 |
8/1/2013
|
|||||||||||
Christopher
J. Pazoles
|
2009 | (1) | — | 200,000 | $ | 0.75 |
12/8/2019
|
|||||||||
2008 | (2) | 66,666 | 133,334 | 0.43 |
12/15/2018
|
|||||||||||
2007 | (2) | 83,333 | 41,667 | 0.45 |
12/17/2017
|
|||||||||||
2006 | (2) | 100,000 | — | 0.91 |
12/11/2016
|
|||||||||||
2005 | (6) | 200,000 | — | 0.01 |
4/8/2015
|
|||||||||||
2004 | (7) | 16,667 | — | 0.01 |
4/1/2014
|
|||||||||||
Elias
B. Nyberg
|
2009 | (1) | — | 150,000 | $ | 0.75 |
12/8/2019
|
|||||||||
2008 | (2) | 33,333 | 66,667 | 0.43 |
12/15/2018
|
|||||||||||
2008 | (8) | 100,000 | — | 0.58 |
4/1/2018
|
(1)
|
These
shares vest quarterly in increments of one-twelfth over three years from
the date of grant. The exercise price equals the closing price on the date
of grant.
|
(2)
|
These
shares vest annually in increments of one-third over three years from the
date of grant. The exercise price equals the closing price on the date of
grant.
|
(3)
|
These
shares initially vested over a two-year period. Pursuant to their terms,
the shares fully vested upon the completion of a non-bridge loan
financing, which occurred in the second quarter of 2005. The exercise
price equals the fair market value of our common stock on the date of
grant as determined by our board of
directors.
|
(4)
|
These
shares initially vested one-third upon grant and one-third annually over
the following two years. Pursuant to their terms, one additional year of
vesting occurred upon the completion of a non-bridge loan financing, which
occurred in the second quarter of 2005. The exercise price equals the fair
market value of our common stock on the date of grant as determined by our
board of directors.
|
(5)
|
These
shares vest annually in increments of one-third over three years from the
date of grant. The exercise price equals the fair market value of our
common stock on the date of grant as determined by our board of
directors.
|
(6)
|
These
shares vested in increments of one-fourth every six months over two years
from the date of grant. The exercise price equals the fair market value of
our common stock on the date of grant as determined by our board of
directors.
|
(7)
|
These
shares represent the fully vested portion of an option grant made to Mr.
Pazoles in consideration of consulting services delivered during 2004.
Pursuant to their terms, the shares vested at the completion of the
consulting engagement and expire ten years from the date of
grant.
|
(8)
|
These
shares were fully vested upon grant. The exercise price equals the closing
price on the date of
grant.
|
Name and Principal Position
|
Year
|
Director
Fees
($) (2)
|
Option
Awards
($) (3)
|
All other
compensation
($)
|
Total ($)
|
|||||||||||||
Stephen
A. Hill, Chairman (1)
|
2009
|
$ | 39,500 | $ | 42,128 | $ | — | $ | 81,628 | |||||||||
Michael
J. Doyle, Director (1)
|
2009
|
32,500 | 42,128 | — | 74,628 | |||||||||||||
Sim
Fass, Director (1)
|
2009
|
33,250 | 42,128 | — | 75,378 | |||||||||||||
James
S. Manuso, Director (1)
|
2009
|
25,250 | 42,128 | — | 67,378 | |||||||||||||
David
B. McWilliams, Director (1)
|
2009
|
26,000 | 42,128 | — | 68,128 | |||||||||||||
Howard
M. Schneider, Director (1)
|
2009
|
38,250 | 42,128 | — | 80,378 |
|
(1)
|
As of December 31, 2009,
outstanding options to purchase common stock held by directors were as
follows: Dr. Hill 350,000; Mr. Doyle 350,000; Dr. Fass 350,000; Dr.
Manuso 300,000; Mr. McWilliams 402,778; Mr. Schneider
250,000.
|
|
(2)
|
Director fees include all fees
earned for director services including quarterly fees, meeting fees and
committee chairman fees.
|
|
(3)
|
The fair value of each stock
award was estimated on the grant date using the Black-Scholes
option-pricing model. See Note 7 to the financial statements for a
description of the assumptions used in estimating the fair value of stock
options.
|
|
·
|
Each person known by us to be the
beneficial owner of more than five percent of our common
stock;
|
|
·
|
Each of our
directors;
|
|
·
|
Each executive officer named in
the summary compensation table;
and
|
|
·
|
All of our current directors and
executive officers as a
group.
|
Shares Beneficially Owned (4)
|
||||||||||||||||
Name and Address of Beneficial
Owner
|
Outstanding
|
Right to Acquire
|
Total
|
Percentage
|
||||||||||||
Purdue
Pharma, L.P. (1)
One
Stamford Forum
201
Tresser Blvd.
Stamford,
CT 06901-3431
|
13,636,364 | 0 | 13,636,364 | 15.1 | ||||||||||||
Knoll
Capital Management (2)
1114
Avenue of the Americas
45
th
Floor
New
York, NY 10036
|
4,462,234 | 9,247,776 | 13,710,010 | 13.7 | ||||||||||||
Harry
S. Palmin (3)
|
641,118 | 1,195,462 | 1,836,580 | 2.0 | ||||||||||||
Christopher
J. Pazoles
|
0 | 383,332 | 383,332 | * | ||||||||||||
Elias
B. Nyberg
|
0 | 158,332 | 158,332 | * | ||||||||||||
Stephen
A. Hill
|
0 | 270,000 | 270,000 | * | ||||||||||||
Michael
J. Doyle
|
0 | 270,000 | 270,000 | * | ||||||||||||
Sim
Fass
|
0 | 270,000 | 270,000 | * | ||||||||||||
James
S. Manuso
|
0 | 220,000 | 270,000 | * | ||||||||||||
David
B. McWilliams
|
0 | 322,778 | 322,778 | * | ||||||||||||
Howard
M. Schneider
|
100,000 | 170,000 | 270,000 | * | ||||||||||||
All
directors and officers as a group (11 persons)
|
741,118 | 3,884,901 | 4,626,019 | 4.9 |
|
*
|
Less than one
percent.
|
Name and Address of Beneficial
Owner
|
Outstanding
Shares of
Common Stock
|
Shares of common
stock issuable upon
automatic
conversion of Series
E Preferred Stock
|
Total pro
forma
ownership
(1)
|
Pro forma
ownership
percentage
(2)
|
||||||||||||
Xmark
Funds (3)
|
||||||||||||||||
90
Grove Street, Suite 201
|
||||||||||||||||
Ridgefield,
CT 06877
|
1,902,096 | 3,652,152 | 5,554,248 | 4.6 | % | |||||||||||
OrbiMed
affiliated funds (4)
|
||||||||||||||||
767
Third Avenue, 30
th
Floor
|
||||||||||||||||
New
York, NY 10017
|
2,284,960 | 3,120,378 | 5,405,338 | 4.4 | % | |||||||||||
Knoll
affiliated funds (5)
|
||||||||||||||||
666
Fifth Avenue, Suite 3702
|
||||||||||||||||
New
York, NY 10103
|
4,462,234 | 9,247,776 | 13,710,010 | 11.2 | % | |||||||||||
Purdue
Pharma, L.P. (6)
|
||||||||||||||||
One
Stamford Forum
|
||||||||||||||||
201
Tresser Blvd.
|
||||||||||||||||
Stamford,
CT 06901-3431
|
13,636,364 | 15,384,614 | 29,020,978 | 23.8 | % |
|
Pro forma ownership does not
include accumulated undeclared dividends totaling approximately $2,092,000
at March 31, 2010 that had not yet been converted as of June 24, 2010.
These accumulated undeclared dividends may be converted into approximately
3,219,000 shares of common stock in connection with the conversion of the
associated remaining shares of Series E preferred
stock.
|
|
(2)
|
Based on 121,907,526 shares of
common stock outstanding, which reflects the number of shares of common
stock outstanding as of June 24, 2010 plus the total number of shares
issuable upon conversion of all of the outstanding shares of Series E
preferred stock (excluding shares issuable upon conversion of accumulated
undeclared dividends).
|
|
Includes Xmark Opportunity
Partners, LLC, Xmark Opportunity Fund, Ltd., Xmark Opportunity Fund, L.P.,
and Xmark JV Investment Partners,
LLC.
|
|
(4)
|
Includes OrbiMed Advisors LLC,
Caduceus Capital Master Fund Limited, Caduceus Capital II, LP, UBS
Eucalyptus Fund, L.L.C., PW Eucalyptus Fund, Ltd., and Summer Street Life
Sciences Investors LLC.
|
|
(5)
|
Includes Knoll Capital, Knoll
Special Opportunities Fund II Master Fund, Ltd., and Europa International,
Inc. As described in footnote 2 to the preceding table, on February 26,
2010, the Knoll-affiliated Funds provided to the Company notice of waiver
of the conversion limitations on the Series E preferred stock held by
them.
|
|
(6)
|
Following the financing
transactions completed on February 11, 2009, August 25, 2009 and November
10, 2009, Purdue transferred its shares of Series E preferred stock,
shares of common stock and warrants to purchase common stock of Novelos to
Beacon Company and Rosebay Medical Company L.P., which are independent
associated companies of Purdue. Pro forma ownership of Purdue excludes
14,003,499 shares of common stock issuable upon exercise of warrants
issued to Purdue in February, August and November 2009 as a result of the
blocker provisions described in footnote 4 to the preceding
table.
|
Plan category
|
Number of shares to
be issued upon
exercise of outstanding
options, warrants and
rights (#)
|
Weighted-average
exercise price of
outstanding options,
warrants and rights
($)
|
Number of shares
remaining available for
future issuance under
equity compensation plans
(excluding shares reflected
in column (a)) (#)
|
|||||||||
(a)
|
(b)
|
(c)
|
||||||||||
Equity
compensation plans approved by stockholders
|
6,766,047 | $ | 0.65 | 3,290,000 | ||||||||
Equity
compensation plans not approved by stockholders
|
2,453,778 | $ | 0.57 | 0 | ||||||||
Total
|
9,219,825 | $ | 0.63 | 3,290,000 |
|
●
|
we will receive funds in the
amount of the aggregate purchase price of the securities being sold by us
on such closing date, less the amount of fees we are paying to the
placement agent;
|
|
●
|
we will cause common stock sold
on such closing date to be delivered in book-entry form through the
facilities of the Depository Trust Company;
and
|
|
●
|
we
will cause an executed warrant exercisable for the applicable number of
shares to be delivered to each purchaser of common stock on such closing
date.
|
Total
|
||||||
$ | $ |
|
·
|
read a copy of the registration
statement, including the exhibits and schedules, without charge at the
SEC’s Public Reference Room;
or
|
|
·
|
obtain a copy from the SEC upon
payment of the fees prescribed by the
SEC.
|
Page
|
|
Report
of Independent Registered Public Accounting Firm
|
F-2
|
Balance
Sheets at March 31, 2010, December 31, 2009 and 2008
|
F-3
|
Statements
of Operations for the Three Months Ended March 31, 2010 and 2009 and the
Years Ended December 31, 2009 and 2008
|
F-4
|
Statements
of Redeemable Preferred Stock and Stockholders’ Deficiency for the Three
Months Ended March 31, 2010 and the Years Ended December 31, 2009 and
2008
|
F-5
|
Statements
of Cash Flows for the Three Months Ended March 31, 2010 and 2009 and the
Years Ended December 31, 2009 and 2008
|
F-6
|
Notes
to Financial Statements
|
F-7
|
Three Months Ended March
31,
|
Year Ended December 31,
|
|||||||||||||||
2010
(unaudited)
|
2009
(unaudited)
|
2009
(audited)
|
2008
(audited)
|
|||||||||||||
REVENUES
|
$ | 8,333 | $ | 30,968 | $ | 96,314 | $ | 125,968 | ||||||||
COSTS
AND EXPENSES:
|
||||||||||||||||
Research
and development
|
1,910,899 | 1,783,832 | 8,080,242 | 14,526,619 | ||||||||||||
General
and administrative
|
644,763 | 476,197 | 2,182,253 | 2,190,366 | ||||||||||||
Total
costs and expenses
|
2,555,652 | 2,260,029 | 10,262,495 | 16,716,985 | ||||||||||||
LOSS
FROM OPERATIONS
|
(2,547,319 | ) | (2,229,061 | ) | (10,166,181 | ) | (16,591,017 | ) | ||||||||
OTHER
INCOME (EXPENSE):
|
||||||||||||||||
Interest
income
|
— | 1,013 | 1,013 | 130,611 | ||||||||||||
Gain
(loss) on derivative warrants (see Note 2)
|
7,897,441 | 412,120 | (12,114,371 | ) | — | |||||||||||
Miscellaneous
|
— | 2,483 | 6,233 | 9,000 | ||||||||||||
Total
other income (expense)
|
7,897,441 | 415,616 | (12,107,125 | ) | 139,611 | |||||||||||
NET
INCOME (LOSS)
|
5,350,122 | (1,813,445 | ) | (22,273,306 | ) | (16,451,406 | ) | |||||||||
PREFERRED
STOCK DIVIDENDS
|
(656,635 | ) | (768,183 | ) | (3,296,289 | ) | (2,092,102 | ) | ||||||||
PREFERRED
STOCK DEEMED DIVIDENDS
|
— | (714,031 | ) | (714,031 | ) | (4,417,315 | ) | |||||||||
NET
INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS
|
$ | 4,693,487 | $ | (3,295,659 | ) | $ | (26,283,626 | ) | $ | (22,960,823 | ) | |||||
BASIC
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON
SHARE
|
$ | 0.06 | $ | (0.07 | ) | $ | (0.53 | ) | $ | (0.56 | ) | |||||
SHARES
USED IN COMPUTING BASIC NET INCOME (LOSS) ATTRIBUTABLE TO COMMON
STOCKHOLDERS PER COMMON SHARE
|
79,919,670 | 43,975,656 | 49,910,010 | 41,100,883 | ||||||||||||
DILUTED
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON
SHARE
|
$ | 0.02 | $ | (0.07 | ) | $ | (0.53 | ) | $ | (0.56 | ) | |||||
SHARES
USED IN COMPUTING DILUTED NET INCOME (LOSS) ATTRIBUTABLE TO COMMON
STOCKHOLDERS PER COMMON SHARE
|
134,925,138 | 43,975,656 | 49,910,010 | 41,100,883 |
REDEEMABLE
PREFERRED STOCK
Series B,
D and E
Convertible
Preferred Stock
|
Common Stock
|
Series C Cumulative
Convertible
Preferred Stock
|
Additional
Paid-in
Capital
|
Accumulated
Deficit
|
Total
Stockholders’
Deficiency
|
|||||||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Par
Amount
|
Shares
|
Par
Amount
|
|||||||||||||||||||||||||||||||
BALANCE
AT JANUARY 1, 2008 (audited)
|
300 | $ | 9,918,666 | 39,260,272 | $ | 392 | 272 | $ | — | $ | 37,370,959 | $ | (43,241,747 | ) | $ | (5,870,396 | ) | |||||||||||||||||||
Exercise
of stock options
|
— | — | 100,000 | 1 | — | — | 999 | — | 1,000 | |||||||||||||||||||||||||||
Compensation
expense associated with options issued to employees
|
— | — | — | — | — | — | 395,194 | — | 395,194 | |||||||||||||||||||||||||||
Compensation
expense associated with options issued to non-employees
|
— | — | — | — | — | — | 58,133 | — | 58,133 | |||||||||||||||||||||||||||
Issuance
of common stock in a private placement
|
— | — | 4,615,384 | 47 | — | — | 2,986,691 | — | 2,986,738 | |||||||||||||||||||||||||||
Issuance
of Series D redeemable convertible preferred stock and warrants, net of
issuance costs of $205,328
|
113.5 | 4,167,080 | — | — | — | — | 1,302,592 | — | 1,302,592 | |||||||||||||||||||||||||||
Adjustment
to record the carrying value of Series D redeemable convertible preferred
stock at market value on the date of sale
|
— | (181,646 | ) | — | — | — | — | 181,646 | — | 181,646 | ||||||||||||||||||||||||||
Fair
value of reduction in conversion and exercise price of Series B redeemable
convertible preferred stock and warrants
|
— | 3,876,912 | — | — | — | — | 722,049 | — | 722,049 | |||||||||||||||||||||||||||
Accretion
of deemed dividend associated with the reduction of conversion and
exercise prices on Series B redeemable convertible preferred stock and
warrants
|
— | (3,876,912 | ) | — | — | — | — | (722,049 | ) | — | (722,049 | ) | ||||||||||||||||||||||||
Dividends
paid on preferred stock
|
— | — | — | — | — | — | (402,780 | ) | — | (402,780 | ) | |||||||||||||||||||||||||
Dividends
accrued on preferred stock
|
— | — | — | — | — | — | (1,689,322 | ) | — | (1,689,322 | ) | |||||||||||||||||||||||||
Net
loss
|
— | — | — | — | — | — | — | (16,451,406 | ) | (16,451,406 | ) | |||||||||||||||||||||||||
BALANCE
AT DECEMBER 31, 2008 (audited)
|
413.5 | 13,904,100 | 43,975,656 | 440 | 272 | — | 40,204,112 | (59,693,153 | ) | (19,488,601 | ) | |||||||||||||||||||||||||
Reclassification
of warrants to derivative liability (see Note 2)
|
— | — | — | — | — | — | (6,893,316 | ) | 5,894,371 | (998,945 | ) | |||||||||||||||||||||||||
Conversion
of Series C convertible preferred stock and accumulated dividends into
common stock
|
— | — | 1,538,837 | 15 | (68 | ) | — | 184,231 | — | 184,246 | ||||||||||||||||||||||||||
Conversion
of Series E convertible preferred stock and accumulated dividends into
common stock
|
(97.18209375 | )) | (3,213,056 | ) | 7,939,008 | 79 | — | — | 3,514,235 | — | 3,514,314 | |||||||||||||||||||||||||
Cashless
exercise of warrants
|
— | — | 483,829 | 5 | — | — | 1,000,957 | — | 1,000,962 | |||||||||||||||||||||||||||
Issuance
of common stock in exchange for warrants
|
— | — | 2,084,308 | 21 | — | — | 1,625,739 | — | 1,625,760 | |||||||||||||||||||||||||||
Issuance
of common stock and warrants in a private placement, net of issuance costs
of $61,116
|
— | — | 13,636,364 | 137 | — | — | 8,938,747 | — | 8,938,884 | |||||||||||||||||||||||||||
Compensation
expense associated with options issued to employees
|
— | — | — | — | — | — | 437,066 | — | 437,066 | |||||||||||||||||||||||||||
Compensation
expense associated with options issued to non-employees
|
— | — | — | — | — | — | 427,271 | — | 427,271 | |||||||||||||||||||||||||||
Issuance
of Series E redeemable convertible preferred stock and warrants, net of
issuance costs of $795,469
|
200 | 6,297,323 | — | — | — | — | 2,907,208 | — | 2,907,208 | |||||||||||||||||||||||||||
Issuance
of Series E redeemable convertible preferred stock in payment of
accumulated dividends
|
31.942875 | 1,597,144 | — | — | — | — | — | — | — | |||||||||||||||||||||||||||
Adjustment
to record the carrying value of Series E redeemable convertible preferred
stock at fair value on the date of sale
|
— | (125,892 | ) | — | — | — | — | 125,892 | — | 125,892 | ||||||||||||||||||||||||||
Fair
value of the extension of expiration date of warrants
|
— | — | — | — | — | — | 839,923 | — | 839,923 | |||||||||||||||||||||||||||
Accretion
of deemed dividend associated with the extension of expiration date of
warrants
|
— | — | — | — | — | — | (839,923 | ) | — | (839,923 | ) | |||||||||||||||||||||||||
Dividends
accrued on preferred stock
|
— | — | — | — | — | — | (3,296,289 | ) | — | (3,296,289 | ) | |||||||||||||||||||||||||
Net
loss
|
— | — | — | — | — | — | — | (22,273,306 | ) | (22,273,306 | ) | |||||||||||||||||||||||||
BALANCE
AT DECEMBER 31, 2009 (audited)
|
548.26078125 | 18,459,619 | 69,658,002 | 697 | 204 | — | 49,175,853 | (76,072,088 | ) | (26,895,538 | ) | |||||||||||||||||||||||||
Exercise
of stock options
|
— | — | 800,000 | 8 | — | — | 157,392 | — | 157,400 | |||||||||||||||||||||||||||
Conversion
of Series E convertible preferred stock and accumulated dividends into
common stock
|
(139.99673625 | ) | (4,689,593 | ) | 11,745,779 | 117 | — | — | 5,324,401 | — | 5,324,518 | |||||||||||||||||||||||||
Cashless
exercise of warrants
|
— | — | 8,182,158 | 82 | — | — | 2,584,315 | — | 2,584,397 | |||||||||||||||||||||||||||
Compensation
expense associated with options issued to employees
|
— | — | — | — | — | — | 140,041 | — | 140,041 | |||||||||||||||||||||||||||
Compensation
expense associated with options issued to non-employees
|
— | — | — | — | — | — | (237,520 | ) | — | (237,520 | ) | |||||||||||||||||||||||||
Dividends
accrued on preferred stock
|
— | — | — | — | — | — | (656,635 | ) | — | (656,635 | ) | |||||||||||||||||||||||||
Net
income
|
— | — | — | — | — | — | — | 5,350,122 | 5,350,122 | |||||||||||||||||||||||||||
BALANCE
AT MARCH 31, 2010 (unaudited)
|
408.264045 | $ | 13,770,026 | 90,385,939 | $ | 904 | 204 | $ | — | $ | 56,487,847 | $ | (70,721,966 | ) | $ | (14,233,215 | ) |
Three Months Ended
March 31,
|
Year Ended
December 31,
|
|||||||||||||||
2010
(unaudited)
|
2009
(unaudited)
|
2009
(audited)
|
2008
(audited)
|
|||||||||||||
CASH
FLOWS FROM OPERATING ACTIVITIES:
|
||||||||||||||||
Net
income (loss)
|
$ | 5,350,122 | $ | (1,813,445 | ) | $ | (22,273,306 | ) | $ | (16,451,406 | ) | |||||
Adjustments
to reconcile net income (loss) to cash used in operating
activities:
|
||||||||||||||||
Depreciation
and amortization
|
27,290 | 6,231 | 32,354 | 16,889 | ||||||||||||
Loss
on disposal of fixed assets
|
— | — | — | 6,472 | ||||||||||||
Stock-based
compensation
|
(97,479 | ) | 126,587 | 864,337 | 453,327 | |||||||||||
(Gain)
loss on derivative warrants
|
(7,897,441 | ) | (412,120 | ) | 12,114,371 | — | ||||||||||
Changes
in:
|
||||||||||||||||
Prepaid
expenses and other current assets
|
(47,574 | ) | 41,290 | 26,862 | 3,496 | |||||||||||
Accounts
payable and accrued liabilities
|
(403,760 | ) | (1,260,400 | ) | (1,354,695 | ) | (1,718,566 | ) | ||||||||
Accrued
compensation
|
(238,022 | ) | (172,381 | ) | 5,072 | (108,773 | ) | |||||||||
Deferred
revenue
|
(8,333 | ) | (8,333 | ) | (33,333 | ) | 466,666 | |||||||||
Cash
used in operating activities
|
(3,315,197 | ) | (3,492,571 | ) | (10,618,338 | ) | (17,331,895 | ) | ||||||||
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
||||||||||||||||
Purchases
of fixed assets
|
— | — | (18,000 | ) | (49,003 | ) | ||||||||||
Change
in restricted cash
|
— | — | — | 1,184,702 | ||||||||||||
Cash
provided by (used in) investing activities
|
— | — | (18,000 | ) | 1,135,699 | |||||||||||
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
||||||||||||||||
Proceeds
from issuance of common stock, net
|
— | 9,204,531 | 8,938,884 | 2,986,738 | ||||||||||||
Proceeds
from issuance of Series D convertible preferred stock and warrants,
net
|
— | — | — | 5,469,672 | ||||||||||||
Proceeds
from issuance of Series E convertible preferred stock and warrants,
net
|
— | — | 9,204,531 | — | ||||||||||||
Dividends
paid to preferred stockholders
|
— | — | — | (740,280 | ) | |||||||||||
Proceeds
from exercise of stock options
|
157,400 | — | — | 1,000 | ||||||||||||
Cash
provided by financing activities
|
157,400 | 9,204,531 | 18,143,415 | 7,717,130 | ||||||||||||
INCREASE
(DECREASE) IN CASH AND EQUIVALENTS
|
(3,157,797 | ) | 5,711,960 | 7,507,077 | (8,479,066 | ) | ||||||||||
CASH
AND EQUIVALENTS AT BEGINNING OF PERIOD
|
8,769,529 | 1,262,452 | 1,262,452 | 9,741,518 | ||||||||||||
CASH
AND EQUIVALENTS AT END OF PERIOD
|
$ | 5,611,732 | $ | 6,974,412 | $ | 8,769,529 | $ | 1,262,452 | ||||||||
SUPPLEMENTAL
DISCLOSURES OF NON-CASH FINANCING ACTIVITIES
|
||||||||||||||||
Dividends
accumulated on shares of Series E preferred stock exchanged or converted
into shares of common stock
|
$ | 634,925 | $ | 1,597,144 | $ | 1,898,402 | $ | — | ||||||||
Dividends
accumulated on shares of Series C preferred stock converted into shares of
common stock
|
$ | — | $ | — | $ | 184,246 | $ | — | ||||||||
Fair
value of derivative warrants upon adoption of new accounting
principle
|
$ | — | $ | 998,945 | $ | 998,945 | $ | — | ||||||||
Fair
value of common stock issued in exchange for tender of derivative
warrants
|
$ | — | $ | — | $ | 1,625,760 | $ | — | ||||||||
Fair
value of derivative warrants reclassified to additional paid-in capital
upon cashless exercise
|
$ | 2,584,397 | $ | — | $ | 1,000,962 | $ | — | ||||||||
Carrying
value of redeemable preferred stock converted into common
stock
|
$ | 4,689,593 | $ | — | $ | 3,213,056 | $ | — | ||||||||
Exchange
of Series B for Series D preferred stock
|
$ | — | $ | — | $ | — | $ | 9,918,666 | ||||||||
Exchange
of Series D for Series E preferred stock
|
$ | — | $ | 13,904,100 | $ | 13,904,100 | $ | — | ||||||||
Relative
fair value of warrants issued to stockholders
|
$ | — | $ | 2,907,208 | $ | 4,835,727 | $ | 1,302,592 |
2009
|
2008
|
|||||||
Office
and computer equipment
|
$
|
73,261
|
$
|
73,261
|
||||
Computer
software
|
43,896
|
25,896
|
||||||
Leasehold
improvements
|
4,095
|
4,095
|
||||||
Total
fixed assets
|
121,252
|
103,252
|
||||||
Less
accumulated depreciation and amortization
|
(77,155
|
)
|
(44,801
|
)
|
||||
Fixed
assets, net
|
$
|
44,097
|
$
|
58,451
|
·
|
Level
1: Input prices quoted in an active market for identical financial assets
or liabilities.
|
|
·
|
Level
2: Inputs other than prices quoted in Level 1, such as prices quoted for
similar financial assets and liabilities in active markets, prices for
identical assets and liabilities in markets that are not active or other
inputs that are observable or can be corroborated by observable market
data.
|
|
·
|
Level
3: Input prices that are significant to the fair value of the financial
assets or liabilities which are not observable or supported by an active
market.
|
March 31, 2010
|
||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Fair Value
|
|||||||||||||
Liabilities:
|
||||||||||||||||
Warrants
|
$
|
-
|
$
|
4,756
|
$
|
-
|
$
|
4,756
|
December 31, 2009
|
||||||||||||||||
Level 1
|
Level 2
|
Level 3
|
Fair Value
|
|||||||||||||
Liabilities:
|
||||||||||||||||
Warrants
|
$
|
-
|
$
|
10,487,000
|
$
|
-
|
$
|
10,487,000
|
5.
|
COLLABORATION
AGREEMENTS
|
Offering
|
Outstanding
(as adjusted)
|
Exercise
Price
(as adjusted)
|
Expiration Date
|
||||||
2005
Bridge Financing
|
400,000
|
$
|
0.625
|
April
1, 2010
|
|||||
2005
Issuance of Common Stock
|
560,826
|
$
|
0.65
|
August
9, 2010
|
|||||
Series
A Preferred Stock (1)
|
909,090
|
$
|
0.65
|
September
30, 2010
|
|||||
2006
Issuance of Common Stock
|
5,548,977
|
$
|
1.72
|
March
7, 2011
|
|||||
Series
B Preferred Stock (2):
|
|||||||||
Purchasers
|
7,500,000
|
$
|
0.65
|
December
31, 2015
|
|||||
Placement
agents
|
900,000
|
$
|
1.25
|
May
2, 2012
|
|||||
Series
C Exchange
|
1,333,333
|
$
|
1.25
|
May
2, 2012
|
|||||
Series
D Preferred Stock (3)
|
4,365,381
|
$
|
0.65
|
December
31, 2015
|
|||||
Series
E Preferred Stock
|
9,230,769
|
$
|
0.65
|
December
31, 2015
|
|||||
August
2009 Private Placement
|
4,772,730
|
$
|
0.66
|
December
31, 2015
|
|||||
Total
|
35,521,106
|
(1)
|
Concurrent with the closing of
the sale of Series B Preferred Stock in 2007, all shares of Series A
Preferred Stock were exchanged for shares of Series C Preferred
Stock.
|
(2)
|
Concurrent
with the closing of the sale of Series D Preferred Stock in 2008, all
shares of Series B Preferred Stock were exchanged for shares of Series D
Preferred Stock.
|
(3)
|
Concurrent
with the closing of the sale of Series E Preferred Stock in 2009, all
shares of Series D Preferred Stock and accumulated unpaid dividends
thereon were exchanged for shares of Series E Preferred
Stock.
|
Offering
|
Outstanding
(as adjusted)
|
Exercise
Price
(as adjusted)
|
Expiration Date
|
||||||
2005
Issuance of Common Stock – placement agents
|
243,476
|
$
|
0.65
|
August
9, 2010
|
|||||
Series
A Preferred Stock
|
909,090
|
$
|
0.65
|
September
30, 2010
|
|||||
2006
Issuance of Common Stock
|
4,557,461
|
$
|
1.72
|
March
7, 2011
|
|||||
Series
B Preferred Stock – placement agents
|
825,000
|
$
|
1.25
|
May
2, 2012
|
|||||
Series
C Exchange
|
1,250,000
|
$
|
1.25
|
May
2, 2012
|
|||||
Series
E Preferred Stock
|
9,230,769
|
$
|
0.65
|
December
31, 2015
|
|||||
August
2009 Private Placement
|
4,772,730
|
$
|
0.66
|
December
31, 2015
|
|||||
Total
|
21,788,526
|
Original private placement
|
Shares of
Common Stock
Issued
|
Warrants
Exercised
|
Exercise
Price
|
Expiration Date
|
|||||||||
2005
Bridge Financing
|
218,648 | 320,000 | $ | 0.625 |
April
1, 2010
|
||||||||
2005
Common Stock
|
200,504 | 485,317 | $ | 0.65 |
August
9, 2010
|
||||||||
Series
A Preferred Stock
|
38,223 | 60,606 | $ | 0.65 |
October
3, 2010
|
||||||||
2006
Issuance of Common Stock
|
26,454 | 201,462 | $ | 1.72 |
March
7, 2011
|
||||||||
Total
|
483,829 | 1,067,385 |
Original private placement
|
Shares of
Common Stock
Issued
|
Warrants
Exercised
|
Exercise
Price
|
|||||||||
2005
Bridge Financing
|
314,982 | 400,000 | $ | 0.625 | ||||||||
2005
Issuance of Common Stock – placement agents
|
226,544 | 317,350 | $ | 0.65 | ||||||||
2006
Issuance of Common Stock
|
366,492 | 991,516 | $ | 1.72 | ||||||||
Series
B Preferred Stock – purchasers
|
4,545,447 | 7,500,000 | $ | 0.65 | ||||||||
Series
B Preferred Stock – placement agents
|
35,106 | 75,000 | $ | 1.25 | ||||||||
Series
D Preferred Stock
|
2,645,685 | 4,365,381 | $ | 0.65 | ||||||||
Series
C Exchange
|
47,902 | 83,333 | $ | 1.25 | ||||||||
Total
|
8,182,158 | 13,732,580 |
March 31,
|
December 31,
|
|||||||||||
2010
|
2009
|
2008
|
||||||||||
2000
Stock Option Plan
|
46,047 | 56,047 | 56,047 | |||||||||
2006
Stock Incentive Plan
|
6,490,000 | 6,710,000 | 4,770,000 | |||||||||
Options
issued outside of formalized plans
|
1,733,778 | 2,453,778 | 2,453,778 | |||||||||
Warrants
|
21,788,526 | 35,521,106 | 28,102,033 | |||||||||
Preferred
stock
|
39,670,569 | 50,406,149 | 36,829,192 | |||||||||
Total
shares reserved for future issuance
|
69,728,920 | 95,147,080 | 72,211,050 |
Three Months Ended March
31,
|
Year Ended
December 31,
|
|||||||||||||||
2010
|
2009
|
2009
|
2008
|
|||||||||||||
Employee
and director stock option grants:
|
||||||||||||||||
Research
and development
|
$ | 57,113 | $ | 36,260 | $ | 148,030 | $ | 159,519 | ||||||||
General
and administrative
|
82,928 | 82,015 | 289,036 | 235,675 | ||||||||||||
140,041 | 118,275 | 437,066 | 395,194 | |||||||||||||
Non-employee
consultant stock option grants and restricted stock
awards:
|
||||||||||||||||
Research
and development
|
(210,825 | ) | 3,329 | 328,614 | 24,131 | |||||||||||
General
and administrative
|
(26,695 | ) | 4,983 | 98,657 | 34,002 | |||||||||||
(237,520 | ) | 8,312 | 427,271 | 58,133 | ||||||||||||
Total
stock-based compensation
|
$ | (97,479 | ) | $ | 126,587 | $ | 864,337 | $ | 453,327 |
Year Ended
December 31,
|
||||||||
2009
|
2008
|
|||||||
Volatility
|
90
|
%
|
80
|
%
|
||||
Weighted-average
volatility
|
90
|
%
|
80
|
%
|
||||
Risk-free
interest rate
|
2.12
|
%
|
1.50%-3.28
|
%
|
||||
Expected
life (years)
|
5
|
5
|
||||||
Dividend
|
0
|
%
|
0
|
%
|
||||
Weighted-average
exercise price
|
$
|
0.75
|
$
|
0.46
|
||||
Weighted-average
grant-date fair value
|
$
|
0.53
|
$
|
0.30
|
Options
Outstanding
|
Weighted
Average
Exercise Price
|
Weighted
Average
Remaining
Contracted
Term in
Years
|
Aggregate
Intrinsic
Value
|
|||||||||||||
Outstanding
at January 1, 2008
|
4,847,651
|
$
|
0.67
|
8.1
|
$
|
1,308,961
|
||||||||||
Options
granted
|
2,560,000
|
$
|
0.46
|
|||||||||||||
Options
exercised
|
(100,000
|
)
|
$
|
0.01
|
||||||||||||
Options
canceled
|
(27,826
|
)
|
$
|
2.23
|
||||||||||||
Outstanding
at December 31, 2008
|
7,279,825
|
$
|
0.60
|
7.9
|
$
|
989,718
|
||||||||||
Options
granted
|
1,940,000
|
$
|
0.75
|
|||||||||||||
Outstanding
at December 31, 2009
|
9,219,825
|
$
|
0.63
|
7.5
|
$
|
17,650,255
|
||||||||||
Options
exercised
|
(800,000
|
)
|
$
|
0.20
|
||||||||||||
Options
canceled
|
(150,000
|
)
|
$
|
2.20
|
||||||||||||
Outstanding
at March 31, 2010
|
8,269,825
|
$
|
0.64
|
7.6
|
$
|
230.992
|
||||||||||
Exercisable
at December 31, 2009
|
5,753,149
|
$
|
0.64
|
6.3
|
$
|
11,031,302
|
||||||||||
Exercisable
at March 31, 2010
|
5,044,805
|
$
|
0.67
|
6.7
|
$
|
230,992
|
2009
|
2008
|
|||||||
Net
operating loss carryforwards
|
$
|
9,543,000
|
$
|
7,128,000
|
||||
Research
and development
expenses
|
14,906,000
|
13,681,000
|
||||||
Tax
credits
|
1,563,000
|
1,311,000
|
||||||
Capital
loss carryforward
|
340,000
|
340,000
|
||||||
Stock-based
compensation
|
650,000
|
449,000
|
||||||
Gross
deferred tax asset
|
27,002,000
|
22,909,000
|
||||||
Valuation
allowance
|
(27,002,000
|
)
|
(22,909,000
|
)
|
||||
Net
deferred tax asset
|
$
|
—
|
$
|
—
|
Numerator:
|
||||
Net
income available to common stockholders used in basic earnings per share
calculation
|
$ |
4,693,487
|
||
Derivative
gain recorded on dilutive warrants
|
(2,340,515)
|
|||
Dividends
on convertible preferred stock
|
656,635
|
|||
Net
income available to common stockholders used in diluted earnings per share
calculation
|
$ |
3,009,607
|
||
Denominator:
|
||||
Weighted
average shares of common stock used in the computation of basic earnings
per share
|
79,919,670
|
|||
Dilutive
effect of stock options
|
4,043,826
|
|||
Dilutive
effect of warrants to purchase common stock
|
12,185,984
|
|||
Dilutive
effect of convertible preferred stock
|
38,775,658
|
|||
Shares
used in computation of diluted earnings per share
|
134,925,138
|
Three Months Ended
March 31,
|
Year Ended
December 31,
|
|||||||||||||||
2010
|
2009
|
2009
|
2008
|
|||||||||||||
|
||||||||||||||||
Stock
options
|
607,463 | 7,279,825 | 9,219,825 | 7,279,825 | ||||||||||||
Warrants
|
6,632,461 | 38,445,170 | 35,521,106 | 28,102,033 | ||||||||||||
Conversion
of preferred stock
|
— | 54,670,982 | (1) | 50,406,149 | (1) | 36,829,192 |
Nature
of Expense
|
Amount
|
|||
SEC
registration fee
|
$
|
813
|
||
Accounting
fees and expenses
|
5,000
|
|||
Legal
fees and expenses
|
75,000
|
|||
Transfer
agent’s fees and expenses
|
3,000
|
|||
Printing
and related fees
|
5,000
|
|||
Miscellaneous
|
||||
Total
|
$
|
88,813
|
·
|
We
issued 11,745,779 shares of our common stock upon conversion of
approximately 140 shares of our Series E preferred stock, having an
aggregate stated value of approximately $7,000,000, and accumulated
undeclared dividends thereon.
|
·
|
We
issued 7,191,132 shares of our common stock upon the cashless exercise of
warrants to purchase 11,865,381 shares of common stock. The
warrants had an expiration date of December 31, 2015 and an exercise price
of $0.65 per share.
|
·
|
We
issued 226,544 shares of our common stock upon the cashless exercise of
warrants to purchase 317,350 shares of common stock. The
warrants had an expiration date of August 9, 2010 and an exercise price of
$0.65 per share.
|
·
|
We
issued 35,106 shares of our common stock upon the cashless exercise of
warrants to purchase 75,000 shares of common stock. The
warrants had an expiration date of May 2, 2012 and an exercise price of
$1.25 per share.
|
·
|
We
issued 366,492 shares of our common stock upon the cashless exercise of
warrants to purchase 991,516 shares of common stock. The warrants had an
expiration date of March 7, 2011 and an exercise price of $1.72 per
share.
|
·
|
We
issued 47,902 shares of our common stock upon the cashless exercise of
warrants to purchase 83,333 shares of common stock. The
warrants had an expiration date of May 2, 2012 and an exercise price of
$1.25 per share.
|
·
|
We
issued 314,982 shares of our common stock upon the cashless exercise of
warrants to purchase 400,000 shares of common stock. The warrants had an
expiration date of April 1, 2010 and an exercise price of $0.625 per
share.
|
·
|
We
issued 4,801,889 shares of our common stock upon conversion of
approximately 58 shares of our Series E preferred stock, having an
aggregate stated value of approximately $2,907,000, and accumulated
undeclared dividends thereon.
|
·
|
We
issued 662,584 shares of our common stock upon conversion of 28 shares of
our Series C preferred stock having an aggregate stated value of $336,000,
and accumulated undeclared dividends
thereon.
|
·
|
We
issued 26,454 shares of our common stock upon the cashless exercise of
warrants to purchase an aggregate of 201,462 shares of common
stock. The warrants had an expiration date of March 7, 2011 and
an exercise price of $1.72 per
share.
|
·
|
We
issued 121,476 shares of our common stock upon the cashless exercise of
warrants to purchase an aggregate of 201,984 shares of common
stock. The warrants had an expiration date of August 9, 2010
and an exercise price of $0.65 per
share.
|
·
|
We
issued 218,648 shares of our common stock upon the cashless exercise of
warrants to purchase an aggregate of 320,000 shares of common
stock. The warrants had an expiration date of April 1, 2010 and
an exercise price of $0.625 per
share.
|
·
|
We
issued 38,223 shares of our common stock upon the cashless exercise of
warrants to purchase an aggregate of 60,606 shares of common
stock. The warrants had an expiration date of October 3, 2010
and an exercise price of $0.65 per
share.
|
·
|
We
sold 8,333,334 shares of our common stock and warrants to purchase
2,916,668 shares of common stock at an exercise price of $0.66 per share
for gross proceeds of approximately
$5,500,000.
|
·
|
We
sold 5,303,030 shares of our common stock and warrants to purchase
1,856,062 shares of common stock at an exercise price of $0.66 per share
for gross proceeds of approximately
$3,500,000.
|
·
|
We
issued 2,084,308 shares of our common stock in exchange for outstanding
warrants to purchase 6,947,728 shares of common stock at an exercise price
of $1.82 per share. These warrants had been issued in a March
2006 financing. The issuance was made pursuant to an exchange
agreement with each warrant holder and was exempt from registration under
Section 3(a)(9) of the Securities
Act.
|
·
|
We
issued 3,137,119 shares of our common stock upon conversion of
approximately 39 shares of our Series E preferred stock, having an
aggregate stated value of approximately $1,952,000, and accumulated
undeclared dividends thereon.
|
·
|
We
issued 114,410 shares of our common stock upon conversion of 5 shares of
our Series C preferred stock, having an aggregate stated value of $60,000,
and accumulated dividends thereon.
|
·
|
We
issued 72,916 shares of our common stock upon the cashless exercise of
warrants to purchase an aggregate of 262,503 shares of common
stock. The warrants had an expiration date of August 9, 2010
and an exercise price of $0.65 per
share.
|
·
|
We
issued 6,112 shares of our common stock upon the cashless exercise of
warrants to purchase an aggregate of 20,830 shares of common
stock. The warrants had an expiration date of August 9, 2010
and an exercise price of $0.65 per
share.
|
·
|
We
issued 761,843 shares of our common stock upon conversion of 35 shares of
our Series C preferred stock, having an aggregate stated value of
$420,000, and accumulated dividends
thereon.
|
·
|
We
sold 200 shares of our Series E preferred stock and warrants to purchase
9,230,769 shares of our common stock at an exercise price of $0.65 per
share for gross proceeds of approximately $10,000,000 and paying
approximately $800,000 in fees and expenses. In addition, 413.5
shares of our Series D preferred stock and accumulated undeclared
dividends thereon were exchanged for 445.442875 shares of our Series E
preferred stock.
|
Filed with
this
Registration
Statement
|
Incorporated by
Reference
|
|||||||||
Exhibit
No.
|
Description
|
on Form
S-1
|
Form
|
Filing Date
|
Exhibit
No.
|
|||||
2.1
|
Agreement
and plan of merger among Common Horizons, Inc., Nove Acquisition, Inc. and
Novelos Therapeutics, Inc. dated May 26, 2005
|
8-K
|
June
2, 2005
|
99.2
|
||||||
2.2
|
Agreement
and plan of merger between Common Horizons and Novelos Therapeutics, Inc.
dated June 7, 2005
|
10-QSB
|
August
15, 2005
|
2.2
|
||||||
3.1
|
Certificate
of Incorporation
|
8-K
|
June
17, 2005
|
1
|
||||||
3.2
|
Certificate
of Designations of Series E convertible preferred
stock
|
8-K
|
February
18, 2009
|
4.1
|
||||||
3.3
|
Certificate
of Designations of Series C cumulative convertible preferred
stock
|
10-QSB
|
May
8, 2007
|
3.2
|
||||||
3.4
|
Certificate
of Amendment of the Amended and Restated Certificate of
Incorporation
|
8-K
|
November
4, 2009
|
3.1
|
||||||
3.5
|
Amended
and Restated By-laws
|
8-K
|
August
26, 2009
|
3.1
|
||||||
4.1
|
Form
of Warrant
|
X
|
||||||||
5.1
|
Legal
Opinion of Foley Hoag LLP
|
|
S-1/A
|
June
25, 2010
|
5.1
|
|||||
10.1
|
Employment
agreement with Christopher J. Pazoles dated July 15, 2005
|
10-QSB
|
August
15, 2005
|
10.4
|
||||||
10.2
|
Employment
Agreement with Harry S. Palmin dated January 31, 2006
|
8-K
|
February
6, 2006
|
99.1
|
||||||
10.3
|
2000
Stock Option and Incentive Plan
|
SB-2
|
November 16, 2005
|
10.2
|
||||||
10.4
|
Form
of 2004 non-plan non-qualified stock option
|
SB-2
|
November 16, 2005
|
10.3
|
||||||
10.5
|
Form
of non-plan non-qualified stock option used from February to May
2005
|
SB-2
|
November 16, 2005
|
10.4
|
||||||
10.6
|
Form
of non-plan non-qualified stock option used after May 2005
|
SB-2
|
November 16, 2005
|
10.5
|
Filed with
this
Registration
Statement
|
Incorporated by
Reference
|
|||||||||
Exhibit
No.
|
Description
|
on Form
S-1
|
Form
|
Filing Date
|
Exhibit
No.
|
|||||
10.7
|
Form
of common stock purchase warrant issued in March 2005
|
SB-2
|
November
16, 2005
|
10.6
|
||||||
10.8
|
Form
of securities purchase agreement dated May 2005
|
8-K
|
June
2, 2005
|
99.1
|
||||||
10.9
|
Form
of subscription agreement dated September 30, 2005
|
8-K
|
October
3, 2005
|
99.1
|
||||||
10.10
|
Form
of Class A common stock purchase warrant dated September 30,
2005
|
8-K
|
October
3, 2005
|
99.3
|
||||||
10.12
|
Consideration
and new technology agreement dated April 1, 2005 with ZAO
BAM
|
10-QSB
|
August
15, 2005
|
10.2
|
||||||
10.13
|
Letter
agreement dated March 31, 2005 with The Oxford Group, Ltd.
|
10-QSB
|
August
15, 2005
|
10.3
|
||||||
10.14
|
Form
of securities purchase agreement dated March 2, 2006
|
8-K
|
March
3, 2006
|
99.2
|
||||||
10.15
|
Form
of common stock purchase warrant dated March 2006
|
8-K
|
March
3, 2006
|
99.3
|
||||||
10.16
|
2006
Stock Incentive Plan, as amended
|
S-1/A
|
December
7, 2009
|
10.16
|
||||||
10.17
|
Form
of Incentive Stock Option under Novelos Therapeutics, Inc.’s 2006 Stock
Incentive Plan
|
8-K
|
December
15, 2006
|
10.1
|
||||||
10.18
|
Form
of Non-Statutory Stock Option under Novelos Therapeutics, Inc.’s 2006
Stock Incentive Plan
|
8-K
|
December
15, 2006
|
10.2
|
||||||
10.19
|
Form
of Non-Statutory Director Stock Option under Novelos Therapeutics, Inc.’s
2006 Stock Incentive Plan
|
8-K
|
December
15, 2006
|
10.3
|
||||||
10.20
|
Securities
Purchase Agreement dated April 12, 2007
|
10-QSB
|
May
8, 2007
|
10.1
|
||||||
10.21
|
Letter
Amendment dated May 2, 2007 to the Securities Purchase
Agreement
|
10-QSB
|
May
8, 2007
|
10.2
|
||||||
10.22
|
Registration
Rights Agreement dated May 2, 2007
|
10-QSB
|
May
8, 2007
|
10.3
|
||||||
10.23
|
Agreement
to Exchange and Consent dated May 1, 2007
|
10-QSB
|
May
8, 2007
|
10.5
|
||||||
10.25
|
Form
of Common Stock Purchase Warrant dated May 2, 2007 issued pursuant to the
Securities Purchase Agreement dated April 12, 2007
|
10-QSB
|
May
8, 2007
|
4.1
|
Filed with
this
Registration
Statement
|
Incorporated by
Reference
|
|||||||||
Exhibit
No.
|
Description
|
on Form
S-1
|
Form
|
Filing Date
|
Exhibit
No.
|
|||||
10.26
|
Form
of Common Stock Purchase Warrant dated May 2, 2007 issued pursuant to the
Agreement to Exchange and Consent dated May 2, 2007
|
10-QSB
|
May
8, 2007
|
4.2
|
||||||
10.27
|
Securities
Purchase Agreement dated March 26, 2008
|
8-K
|
April
14, 2008
|
10.1
|
||||||
10.28
|
Amendment
to Securities Purchase Agreement dated April 9, 2008
|
8-K
|
April
14, 2008
|
10.2
|
||||||
10.29
|
Registration
Rights Agreement dated April 11, 2008
|
8-K
|
April
14, 2008
|
10.3
|
||||||
10.30
|
Form
of Common Stock Purchase Warrant dated April 11, 2008 issued pursuant to
the Securities Purchase Agreement dated March 26, 2008
|
8-K
|
April
14, 2008
|
4.3
|
||||||
10.31
|
Warrant
Amendment Agreement dated April 11, 2008
|
8-K
|
April
14, 2008
|
10.5
|
||||||
10.32
|
Amendment
to Registration Rights Agreement dated April 11, 2008
|
8-K
|
April
14, 2008
|
10.4
|
||||||
10.33
|
Securities
Purchase Agreement dated August 14, 2008
|
8-K
|
August
18, 2008
|
10.1
|
||||||
10.34
|
Securities
Purchase Agreement dated February 11, 2009
|
8-K
|
February
18, 2009
|
10.1
|
||||||
10.35
|
Registration
Rights Agreement dated February 11, 2009
|
8-K
|
February
18, 2009
|
10.2
|
||||||
10.36
|
Series
D Preferred Stock Consent and Agreement to Exchange dated February 10,
2009
|
8-K
|
February
18, 2009
|
10.3
|
||||||
10.37
|
Warrant
Amendment Agreements dated February 11, 2009
|
8-K
|
February
18, 2009
|
10.4
|
||||||
10.38
|
Amendment
No. 2 to Registration Rights Agreement dated February 11,
2009
|
8-K
|
February
18, 2009
|
10.5
|
||||||
10.39
|
Collaboration
Agreement dated February 11, 2009*
|
10-K
|
March
30, 2009
|
10.39
|
||||||
10.40
|
Form
of Warrant Exchange Agreement dated August 21, 2009
|
8-K
|
August
26, 2009
|
10.5
|
||||||
10.41
|
Securities
Purchase Agreement dated August 25, 2009
|
S-1
|
September
15, 2009
|
10.41
|
||||||
10.42
|
Registration
Rights Agreement dated August 25, 2009
|
S-1
|
September
15, 2009
|
10.42
|
10.43
|
Common
Stock Purchase Warrant dated August 25,2009
|
S-1
|
September
15, 2009
|
10.43
|
||||||
10.44
|
Letter
Agreement with LP Clover Limited dated August 25, 2009
|
S-1
|
September
15, 2009
|
10.44
|
||||||
10.45
|
Letter
Agreement with Mundipharma International Corporation Limited dated August
25, 2009
|
S-1
|
September
15, 2009
|
10.45
|
||||||
10.46
|
Summary
of Phase 3 Clinical Trial Bonus Plan adopted on December 8,
2009
|
S-1/A
|
January
26, 2010
|
10.46
|
||||||
10.47
|
Consent
and Amendment Agreement dated January 21, 2010
|
S-1/A
|
January
26, 2010
|
10.47
|
||||||
10.48
|
Form
of Executive Retention Agreement dated May 14, 2010
|
10-Q
|
May
17, 2010
|
10.3
|
||||||
10.49
|
Letter
dated May 14, 2010 terminating Employment Agreement dated July 15, 2005
between the Company and Christopher J. Pazoles
|
10-Q
|
May
17, 2010
|
10.4
|
||||||
10.50
|
Form
of Placement Agent Agreement between the Company and Rodman and
Renshaw LLC
|
|
S-1/A
|
June
25, 2010
|
10.50
|
|||||
10.51
|
Form
of Securities Purchase Agreement
|
X
|
||||||||
10.52
|
Written
Consent and Waiver of Holders of Series C Convertible Preferred Stock and
Series E Convertible Preferred Stock dated July 6,
2010
|
X
|
||||||||
10.53
|
Form of Common Stock Purchase Warrant to be issued pursuant to the Consent and Waiver of Holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock dated July 6, 2010 |
X
|
||||||||
23.1
|
Consent
of Foley Hoag (included in Exhibit 5.1)
|
S-1/A
|
June
25, 2010
|
23.1
|
||||||
23.2
|
Consent
of Stowe & Degon LLC
|
X
|
||||||||
24.1
|
|
Powers
of Attorney (included on signature page)
|
|
|
|
S-1
|
May
11, 2010
|
24.1
|
NOVELOS
THERAPEUTICS, INC.
|
|
By:
|
/s/
Harry S. Palmin
|
Harry
S. Palmin
|
|
President
and Chief Executive
Officer
|
Signature
|
Title
|
Date
|
||
/s/
Harry S. Palmin
|
Chief
Executive Officer and Director
|
|||
Harry
S. Palmin
|
(
principal
executive officer
)
|
July
7, 2010
|
||
/s/
Joanne M. Protano
|
Chief
Financial Officer
|
July
7, 2010
|
||
Joanne
M. Protano
|
(
principal financial officer and principal accounting officer)
|
|||
/s/
*
|
Chairman
of the Board of Directors
|
July
7, 2010
|
||
Stephen
A. Hill
|
||||
/s/
*
|
Director
|
July
7, 2010
|
||
Michael
J. Doyle
|
||||
/s/
*
|
Director
|
July
7, 2010
|
||
Sim
Fass
|
||||
/s/
*
|
Director
|
July
7, 2010
|
||
James
S. Manuso
|
||||
/s/
*
|
Director
|
July
7, 2010
|
||
David
B. McWilliams
|
||||
/s/
*
|
|
Director
|
|
July
7, 2010
|
Howard
M. Schneider
|
Filed with
this
Registration
Statement
|
Incorporated by
Reference
|
|||||||||
Exhibit
No.
|
Description
|
on Form
S-1
|
Form
|
Filing Date
|
Exhibit
No.
|
|||||
2.1
|
Agreement
and plan of merger among Common Horizons, Inc., Nove Acquisition, Inc. and
Novelos Therapeutics, Inc. dated May 26, 2005
|
8-K
|
June
2, 2005
|
99.2
|
||||||
2.2
|
Agreement
and plan of merger between Common Horizons and Novelos Therapeutics, Inc.
dated June 7, 2005
|
10-QSB
|
August
15, 2005
|
2.2
|
||||||
3.1
|
Certificate
of Incorporation
|
8-K
|
June
17, 2005
|
1
|
||||||
3.2
|
Certificate
of Designations of Series E convertible preferred
stock
|
8-K
|
February
18, 2009
|
4.1
|
||||||
3.3
|
Certificate
of Designations of Series C cumulative convertible preferred
stock
|
10-QSB
|
May
8, 2007
|
3.2
|
||||||
3.4
|
Certificate
of Amendment of the Amended and Restated Certificate of
Incorporation
|
8-K
|
November
4, 2009
|
3.1
|
||||||
3.5
|
Amended
and Restated By-laws
|
|
8-K
|
August
26, 2009
|
3.1
|
|||||
4.1
|
Form
of Warrant
|
X
|
||||||||
5.1
|
Legal
Opinion of Foley Hoag LLP
|
S-1/A
|
June
25, 2010
|
5.1
|
||||||
10.1
|
Employment
agreement with Christopher J. Pazoles dated July 15, 2005
|
10-QSB
|
August
15, 2005
|
10.4
|
||||||
10.2
|
Employment
Agreement with Harry S. Palmin dated January 31, 2006
|
8-K
|
February
6, 2006
|
99.1
|
||||||
10.3
|
2000
Stock Option and Incentive Plan
|
SB-2
|
November
16, 2005
|
10.2
|
||||||
10.4
|
Form
of 2004 non-plan non-qualified stock option
|
SB-2
|
November
16, 2005
|
10.3
|
||||||
10.5
|
Form
of non-plan non-qualified stock option used from February to May
2005
|
SB-2
|
November
16, 2005
|
10.4
|
||||||
10.6
|
Form
of non-plan non-qualified stock option used after May 2005
|
SB-2
|
November
16, 2005
|
10.5
|
Filed with
this
Registration
Statement
|
Incorporated by
Reference
|
|||||||||
Exhibit
No.
|
Description
|
on Form
S-1
|
Form
|
Filing Date
|
Exhibit
No.
|
|||||
10.7
|
Form
of common stock purchase warrant issued in March 2005
|
SB-2
|
November
16, 2005
|
10.6
|
||||||
10.8
|
Form
of securities purchase agreement dated May 2005
|
8-K
|
June
2, 2005
|
99.1
|
||||||
10.9
|
Form
of subscription agreement dated September 30, 2005
|
8-K
|
October
3, 2005
|
99.1
|
||||||
10.10
|
Form
of Class A common stock purchase warrant dated September 30,
2005
|
8-K
|
October
3, 2005
|
99.3
|
||||||
10.12
|
Consideration
and new technology agreement dated April 1, 2005 with ZAO
BAM
|
10-QSB
|
August
15, 2005
|
10.2
|
||||||
10.13
|
Letter
agreement dated March 31, 2005 with The Oxford Group, Ltd.
|
10-QSB
|
August
15, 2005
|
10.3
|
||||||
10.14
|
Form
of securities purchase agreement dated March 2, 2006
|
8-K
|
March
3, 2006
|
99.2
|
||||||
10.15
|
Form
of common stock purchase warrant dated March 2006
|
8-K
|
March
3, 2006
|
99.3
|
||||||
10.16
|
2006
Stock Incentive Plan, as amended
|
S-1/A
|
December
7, 2009
|
10.16
|
||||||
10.17
|
Form
of Incentive Stock Option under Novelos Therapeutics, Inc.’s 2006 Stock
Incentive Plan
|
8-K
|
December
15, 2006
|
10.1
|
||||||
10.18
|
Form
of Non-Statutory Stock Option under Novelos Therapeutics, Inc.’s 2006
Stock Incentive Plan
|
8-K
|
December
15, 2006
|
10.2
|
||||||
10.19
|
Form
of Non-Statutory Director Stock Option under Novelos Therapeutics, Inc.’s
2006 Stock Incentive Plan
|
8-K
|
December
15, 2006
|
10.3
|
||||||
10.20
|
Securities
Purchase Agreement dated April 12, 2007
|
10-QSB
|
May
8, 2007
|
10.1
|
||||||
10.21
|
Letter
Amendment dated May 2, 2007 to the Securities Purchase
Agreement
|
10-QSB
|
May
8, 2007
|
10.2
|
||||||
10.22
|
Registration
Rights Agreement dated May 2, 2007
|
10-QSB
|
May
8, 2007
|
10.3
|
||||||
10.23
|
Agreement
to Exchange and Consent dated May 1, 2007
|
10-QSB
|
May
8, 2007
|
10.5
|
Filed with
this
Registration
Statement
|
Incorporated by
Reference
|
|||||||||
Exhibit
No.
|
Description
|
on Form
S-1
|
Form
|
Filing Date
|
Exhibit
No.
|
|||||
10.25
|
Form
of Common Stock Purchase Warrant dated May 2, 2007 issued pursuant to the
Securities Purchase Agreement dated April 12, 2007
|
10-QSB
|
May
8, 2007
|
4.1
|
||||||
10.26
|
Form
of Common Stock Purchase Warrant dated May 2, 2007 issued pursuant to the
Agreement to Exchange and Consent dated May 2, 2007
|
10-QSB
|
May
8, 2007
|
4.2
|
||||||
10.27
|
Securities
Purchase Agreement dated March 26, 2008
|
8-K
|
April
14, 2008
|
10.1
|
||||||
10.28
|
Amendment
to Securities Purchase Agreement dated April 9, 2008
|
8-K
|
April
14, 2008
|
10.2
|
||||||
10.29
|
Registration
Rights Agreement dated April 11, 2008
|
8-K
|
April
14, 2008
|
10.3
|
||||||
10.30
|
Form
of Common Stock Purchase Warrant dated April 11, 2008 issued pursuant to
the Securities Purchase Agreement dated March 26, 2008
|
8-K
|
April
14, 2008
|
4.3
|
||||||
10.31
|
Warrant
Amendment Agreement dated April 11, 2008
|
8-K
|
April
14, 2008
|
10.5
|
||||||
10.32
|
Amendment
to Registration Rights Agreement dated April 11, 2008
|
8-K
|
April
14, 2008
|
10.4
|
||||||
10.33
|
Securities
Purchase Agreement dated August 14, 2008
|
8-K
|
August
18, 2008
|
10.1
|
||||||
10.34
|
Securities
Purchase Agreement dated February 11, 2009
|
8-K
|
February
18, 2009
|
10.1
|
||||||
10.35
|
Registration
Rights Agreement dated February 11, 2009
|
8-K
|
February
18, 2009
|
10.2
|
||||||
10.36
|
Series
D Preferred Stock Consent and Agreement to Exchange dated February 10,
2009
|
8-K
|
February
18, 2009
|
10.3
|
||||||
10.37
|
Warrant
Amendment Agreements dated February 11, 2009
|
8-K
|
February
18, 2009
|
10.4
|
||||||
10.38
|
Amendment
No. 2 to Registration Rights Agreement dated February 11,
2009
|
8-K
|
February
18, 2009
|
10.5
|
||||||
10.39
|
Collaboration
Agreement dated February 11, 2009*
|
10-K
|
March
30, 2009
|
10.39
|
||||||
10.40
|
Form
of Warrant Exchange Agreement dated August 21, 2009
|
8-K
|
August
26, 2009
|
10.5
|
10.41
|
Securities
Purchase Agreement dated August 25, 2009
|
S-1
|
September
15, 2009
|
10.41
|
||||||
10.42
|
Registration
Rights Agreement dated August 25, 2009
|
S-1
|
September
15, 2009
|
10.42
|
||||||
10.43
|
Common
Stock Purchase Warrant dated August 25,2009
|
S-1
|
September
15, 2009
|
10.43
|
||||||
10.44
|
Letter
Agreement with LP Clover Limited dated August 25, 2009
|
S-1
|
September
15, 2009
|
10.44
|
||||||
10.45
|
Letter
Agreement with Mundipharma International Corporation Limited dated August
25, 2009
|
S-1
|
September
15, 2009
|
10.45
|
||||||
10.46
|
Summary
of Phase 3 Clinical Trial Bonus Plan adopted on December 8,
2009
|
S-1/A
|
January
26, 2010
|
10.46
|
||||||
10.47
|
Consent
and Amendment Agreement dated January 21, 2010
|
S-1/A
|
January
26, 2010
|
10.47
|
||||||
10.48
|
Form
of Executive Retention Agreement dated May 14, 2010
|
10-Q
|
May
17, 2010
|
10.3
|
||||||
10.49
|
Letter
dated May 14, 2010 terminating Employment Agreement dated July 15, 2005
between the Company and Christopher J. Pazoles
|
10-Q
|
May
17, 2010
|
10.4
|
||||||
10.50
|
Form
of Placement Agent Agreement between the Company and Rodman and
Renshaw LLC
|
|
S-1/A
|
June
25, 2010
|
10.50
|
|||||
10.51
|
Form
of Securities Purchase Agreement
|
X
|
||||||||
10.52
|
Written
Consent and Waiver of Holders of Series C Convertible Preferred Stock and
Series E Convertible Preferred Stock dated July 6,
2010
|
X
|
||||||||
10.53
|
Form of Common Stock Purchase Warrant to be issued pursuant to the Consent and Waiver of Holders of Series C Convertible Preferred Stock and Series E Convertible Preferred Stock dated July 6, 2010 |
X
|
||||||||
23.1
|
Consent
of Foley Hoag (included in Exhibit 5.1)
|
|
S-1/A
|
June
25, 2010
|
23.1
|
|||||
23.2
|
Consent
of Stowe & Degon LLC
|
X
|
||||||||
24.1
|
|
Powers
of Attorney (included on signature page)
|
|
|
|
S-1
|
May
11, 2010
|
24.1
|
Warrant
Shares: [_______
|
Initial
Exercise Date: July ______,
2010
|
(A)
=
|
the
VWAP on the Trading Day immediately preceding the date on which Holder
elects to exercise this Warrant by means of a “cashless exercise,” as set
forth in the applicable Notice of
Exercise;
|
(B)
=
|
the
Exercise Price of this Warrant, as adjusted hereunder;
and
|
(X)
=
|
the
number of Warrant Shares that would be issuable upon exercise of this
Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless
exercise.
|
NOVELOS
THERAPEUTICS, INC.
|
By:__________________________________________
Name:
Title:
|
Name of Investing Entity: |
|
Signature of Authorized Signatory of Investing Entity : | |
Name of Authorized Signatory: | |
Title of Authorized Signatory: | |
Date: |
whose address
is
|
|
.
|
|
Holder’s
Signature:
|
||
Holder’s
Address:
|
||
W
|
=
|
Warrant
Share Factor.
|
C
|
=
|
Number
of shares of Common Stock issuable upon such Holder’s Series C Preferred
Stock or Series E Preferred Stock, as applicable.
|
Pc
|
=
|
Pre-Transaction
conversion price per share of Common Stock for Series C Preferred Stock or
Series E Preferred Stock, as applicable.
|
Px
|
=
|
the
volume weighted average price of the Common Stock as reported on Bloomberg
LP for the 20 Trading Day period immediately following the consummation of
the
Transaction.
|
SERIES
E HOLDERS:
|
|
XMARK
OPPORTUNITY FUND, LTD.
|
CADUCEUS
CAPITAL MASTER FUND
|
XMARK
OPPORTUNITY FUND, L.P.
|
LIMITED
|
XMARK
JV INVESTMENT
|
CADUCEUS
CAPITAL II, L.P.
|
PARTNERS,
LLC
|
UBS
EUCALYPTUS FUND, L.L.C.
|
|
PW
EUCALYPTUS FUND, LTD.
|
SUMMER
STREET LIFE SCIENCES
|
|
HEDGE FUND INVESTORS LLC | |
By:
/s/ Mitchell D.
Kaye
|
By:
_______________________
|
Name:
Mitchell D. Kaye
|
Name:
Samuel D. Isaly
|
Title:
Authorized Signatory
|
Title:
Managing Partner, Orbimed Advisors
|
Address:
90 Grove Street
|
Address:
c/o OrbiMed Advisors LLC
|
Ridgefield,
CT 06877
|
767
Third Avenue, 30th Floor
|
Attn:
Mitchell D. Kaye
|
New
York, NY
10017
|
BEACON
COMPANY
|
ROSEBAY
MEDICAL COMPANY, L.P.
|
By:
Stanhope Gate Corp., its managing
|
By:
Rosebay Medical Company, Inc., its
|
general
partner
|
general
partner
|
By:
/s/ Steven
Meiklejohn
|
By:
/s/ Stephen A.
Ives
|
Name:
Steven Meiklejohn
|
Name:
Stephen A. Ives
|
Title:
Director
|
Title:
Vice
President
|
|
|
LONGVIEW
FUND, LP
|
LONGVIEW
EQUITY FUND, LP
|
By:
/s/ Peter T.
Benz
|
By:
/s/ Peter T.
Benz
|
Name:
Peter T. Benz
|
Name:
Peter T. Benz
|
Title:
Manager
|
Title:
Manager
|
Address:
|
Address:
|
NOVELOS
THERAPEUTICS, INC.
|
|
Dated:
July 6, 2010
|
|
By:
/s/ Harry S.
Palmin
|
|
Name:
Harry S. Palmin
|
|
Title:
President and CEO
|
Warrant
No. [_]
|
|
Original
Issue Date: [ ], 2010
|
NOVELOS
THERAPEUTICS, INC.
|
|||
By:
|
|||
Name:
|
Harry
S. Palmin
|
||
Title:
|
President
and CEO
|
_______________________________
|
Name
|
________________________________
|
Address
|
________________________________
|
________________________________
|
Federal
Tax ID or Social Security
No.
|
o
|
certified
mail to the above address, or
|
o
|
electronically
(provide DWAC Instructions:___________________), or
|
o
|
other
(specify:
__________________________________________).
|
Note:
The signature must correspond with
|
|
the
name of the registered holder as written
|
Signature:_______________________
|
on
the first page of the Warrant in every
|
_______________________________
|
particular,
without alteration or enlargement
|
Name
(please print)
|
or
any change whatever, unless the Warrant
|
|
has
been assigned.
|
_______________________________
|
_______________________________
|
|
Address
|
|
_______________________________
|
|
Federal
Identification or
|
|
Social
Security No.
|
|
Assignee:
|
|
_______________________________
|
|
_______________________________
|
|
_______________________________
|
|
||
Signature
|
||
|
||
Name for Registration
|
||
|
||
Mailing Address
|
/s/
Stowe & Degon LLC
|
Westborough,
Massachusetts
|
July
6, 2010
|